Retrospective review of modafinil use for cerebral palsy

Journal of Child Neurology

Volumn 19, Issue 12, 2004, Pages 948-951

  Hurst, Daniel L ^a,b   Lajara Nanson, Walter A ^a   Dinakar, Pradeep ^a   Schiffer, Randolph B ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL;

ANOREXIA; CEREBRAL PALSY; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG RESPONSE; HUMAN; HYPERACTIVITY; IRRITABILITY; JOINT MOBILITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 13444271922     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190120701     Document Type: Review

References (27)

1. Hurst DL, Lajara-Nanson W: Use of modafinil in spastic cerebral palsy. J Child Neurol 2002;17:169-172.
2. Lin JS, Hou Y, Jovet M: Potential brain neuronal targets for amphetamine-,methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996;93:14128-14133.
3. A receptor blockade. Neuropsychopharmacology 1999;20:346-356.
4. Simon P, Hémet C, Ramassamy C, et al: Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995;5:509-514.
5. Simon P, Hémet C, Costentin J: Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 1996;10:431-435.
6. Duteil J, Rambert FA, Pessonnier J, et al: Central α1-adrenergic stimulation in relation to the behavior stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 1990;180:49-58.
7. H-NMR study. Brain Res 1995;693:251-256.
8. Ferraro L, Antonelli T, O'Connor WT, et al: The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: Evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998; 253:135-138.
9. Engber TM, Dennis SA, Jones BE, et al: Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience 1998;87: 905-911.
10. Ferraro L, Antonelli T, O'Connor WT, et al: The antinarcoleptic drug modafinil increases glutamate release in the thalamic areas and hippocampus. Neuroreport 1997;8:2883-2887.
11. Rammohan KW, Rosenberg JH, Lynn DJ, et al: Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-183.
12. Krupp LB, Elkins LE: Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000;55:934-939.
13. Bakshi R, Miletich RS, Kinkel PR, et al: High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998;8:228-234.
14. 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566-1571.
15. Moldofsky H, Broughton RJ, Hill JD: A randomized trial of the long-term continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-116.
16. Broughton RJ, Fleming JAE, George CFP, et al: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
17. US Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
18. Rugino TA, Copley TC: Effects of modafinil in children with attention-deficit hyperactivity disorder: An open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-235.
19. Fox AM, Rieder MJ: Risks and benefits of drugs used in the management of the hyperactive child. Drug Saf 1993;9:38-50.
20. Klein RG, Landa B, Mattes JA, et al: Methylphenidate and growth in hyperactive children: A controlled withdrawal study. Arch Gen Psychiatry 1988;45:1127-1130.
21. Schachar RJ, Tannock R, Cunningham C, et al: Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36: 754-763.
22. Schertz M, Adesman AR, Alfieri NE, et al: Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 1996;98:763-769.
23. Milla PJ, Jackson ADM: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1997;5:398-404.
24. Gilmartin R, Bruce D, Storrs B, et al: Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. J Child Neurol 2000;15:71-77.
25. Fehlings D, Rang M, Glazier J, et al: An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-337.
26. Nelson KB: Epidemiology of Cerebral Palsy in the Year 2000 Presented at the 29th Annual Meeting of the Child Neurology Society, St. Louis, MO, October 28, 2000.
27. Hagberg B, Hagberg G, Olow I, et al: The changing panorama of cerebral palsy in Sweden: VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 1996;85:954-960.